Chemotherapy最新文献

英文中文

Primary squamous cell carcinoma of the duodenum: a case report and literature review. 十二指肠原发性鳞状细胞癌：病例报告和文献综述。

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy

Pub Date : 2024-11-11 DOI: 10.1159/000542485

Yifan Hui, Fei Ke, Wei Lu, Wenli Qiu, Xia Zheng, Haibo Cheng

Duodenal squamous cell carcinoma is an exceedingly rare occurrence among gastrointestinal malignancies, and its diagnosis and treatment are not well understood. In this report, we present a case of duodenal squamous cell carcinoma with liver and adrenal metastasis. The patient was treated with gemcitabine and S-1, achieving a progression-free survival (PFS) of 7 months and an overall survival (OS) of 9 months. Additionally, we review the features and treatment approaches reported in previous cases of primary duodenal carcinoma. Clearly, further case reports, such as ours, can contribute to a deeper understanding that is essential for characterizing this entity and establishing management guidelines.

十二指肠鳞状细胞癌在胃肠道恶性肿瘤中极为罕见，其诊断和治疗方法也不甚明了。在本报告中，我们介绍了一例十二指肠鳞状细胞癌伴有肝脏和肾上腺转移的病例。患者接受了吉西他滨和S-1治疗，获得了7个月的无进展生存期（PFS）和9个月的总生存期（OS）。此外，我们还回顾了以往报道的原发性十二指肠癌病例的特点和治疗方法。显然，进一步的病例报告（如我们的报告）有助于加深对这一病例的了解，这对于确定该病例的特征和制定治疗指南至关重要。

引用次数: 0

Predicting reprisal of solid cancer treatment and 60-month survival after Medical Intensive Care. A single-centre cohort study. 预测对实体癌治疗的报复和医疗重症监护后 60 个月的生存率。单中心队列研究。

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy

Pub Date : 2024-11-09 DOI: 10.1159/000542101

Victoria Ferrari, Lucas Morand, Hervé Hyvernat, Renaud Schiappa, Jean Dellamonica, Nihal Martis

Introduction: Our study aimed to identify relevant features associated with the reprisal of antineoplastic treatment in patients with solid cancers after unplanned admittance to the intensive care unit (ICU) and to assess 60th-month survival in patients with solid neoplasms admitted to the ICU.

Methods: This single-centre retrospective study of critically ill patients with active cancers was performed over a 13-year period (2005-2018). Patients' characteristics, overall survival and antineoplastic treatment reprisal were extracted from digital medical files and compared.

Results: 134 patients were included in the study. Solid neoplasms were mostly localised to the head and neck (n=53) followed by lung cancers (n=29). Sepsis was the leading cause of ICU admission (62.1%) with 41/82 patients presenting with septic shock. Antineoplastic treatments were resumed in 40 patients. An age ≤60 years and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 were found to be predictors for treatment reprisal, with odd ratios of, respectively, 2.83 (95%CI, 1.15-6.99) and 5.45 (95%CI, 2.01-14.82); area under the ROC curve of 72% (95%CI, 63-81%). Survival after the immediate discharge from the ICU was 101/134 (75%) and the 60-month survival rate was 29% and significantly higher in the treatment-reprisal group.

Conclusions: Age and ECOG PS were found to be predictors for treatment reprisal in patients with solid neoplasms admitted to the ICU. The latter benefit from better long-term survival.

简介我们的研究旨在确定实体瘤患者意外入住重症监护室（ICU）后重新接受抗肿瘤治疗的相关特征，并评估入住重症监护室的实体瘤患者的第60个月生存率：这项针对活动性癌症重症患者的单中心回顾性研究历时13年（2005-2018年）。研究人员从数字医疗档案中提取了患者的特征、总生存率和抗肿瘤治疗反响，并进行了比较：研究共纳入 134 名患者。实体瘤多发于头颈部（53例），其次是肺癌（29例）。脓毒症是入住重症监护病房的主要原因（62.1%），其中41/82名患者出现脓毒性休克。40名患者恢复了抗肿瘤治疗。研究发现，年龄≤60岁和东部合作肿瘤学组（ECOG）表现状态（PS）≤1是治疗恢复的预测因素，奇异比分别为2.83（95%CI，1.15-6.99）和5.45（95%CI，2.01-14.82）；ROC曲线下面积为72%（95%CI，63-81%）。重症监护室出院后的存活率为101/134（75%），60个月的存活率为29%，治疗-再治疗组的存活率明显更高：结论：研究发现，年龄和 ECOG PS 是重症监护室收治的实体瘤患者重新接受治疗的预测因素。后者的长期生存率更高。

{"title":"Predicting reprisal of solid cancer treatment and 60-month survival after Medical Intensive Care. A single-centre cohort study.","authors":"Victoria Ferrari, Lucas Morand, Hervé Hyvernat, Renaud Schiappa, Jean Dellamonica, Nihal Martis","doi":"10.1159/000542101","DOIUrl":"https://doi.org/10.1159/000542101","url":null,"abstract":"Introduction: Our study aimed to identify relevant features associated with the reprisal of antineoplastic treatment in patients with solid cancers after unplanned admittance to the intensive care unit (ICU) and to assess 60th-month survival in patients with solid neoplasms admitted to the ICU.Methods: This single-centre retrospective study of critically ill patients with active cancers was performed over a 13-year period (2005-2018). Patients' characteristics, overall survival and antineoplastic treatment reprisal were extracted from digital medical files and compared.Results: 134 patients were included in the study. Solid neoplasms were mostly localised to the head and neck (n=53) followed by lung cancers (n=29). Sepsis was the leading cause of ICU admission (62.1%) with 41/82 patients presenting with septic shock. Antineoplastic treatments were resumed in 40 patients. An age ≤60 years and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤1 were found to be predictors for treatment reprisal, with odd ratios of, respectively, 2.83 (95%CI, 1.15-6.99) and 5.45 (95%CI, 2.01-14.82); area under the ROC curve of 72% (95%CI, 63-81%). Survival after the immediate discharge from the ICU was 101/134 (75%) and the 60-month survival rate was 29% and significantly higher in the treatment-reprisal group.Conclusions: Age and ECOG PS were found to be predictors for treatment reprisal in patients with solid neoplasms admitted to the ICU. The latter benefit from better long-term survival.","PeriodicalId":10047,"journal":{"name":"Chemotherapy","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Chemotherapy

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀